藥明系急瀉殃及同業 百濟神州及金斯瑞挫8%至9% 復星醫藥創逾十年低
藥明系今日(2日)午後跌幅曾擴至19%至26%齊尋底;生科醫藥股也普遍難獨善其身,金斯瑞(01548.HK)低見12.66元(暫守52周低位12.64元),現報12.86元,跌8.8%。百濟神州(06160.HK)低見83.25元創逾15個月低,現報83.55元,挫8%。
信達生物(01801.HK)、榮昌生物(09995.HK)、歌禮製藥-B(01672.HK)、康方生物(09926.HK)及康希諾生物(06185.HK)跌逾3.5%至5%,後者股價曾低見15.78元再創上市新低,現報15.92元,跌5%。復星醫藥(02196.HK)跌見13.04元再創逾十年低,現報13.18元,跌3.9%。
然而,開拓藥業-B(09939.HK)旗下治療脫髮藥獲批臨床試驗,股價由低位止跌回升兼重越10天及20天線,曾飆47%高見1.76元,現報1.63元,急漲36%,成交激增至1.2億股,涉近2億元。騰盛博藥(02137.HK)止跌,股價由上市低位反彈,最高曾見1.86元遇壓,現報1.66元,回升3.1%。
其餘藍籌醫藥股方面,石藥(01093.HK)微跌0.1%、中生製藥(01177.HK)及國藥控股跌1.7%至2.2%、翰森(03692.HK)挫4.9%。線上醫藥股阿里健康(00241.HK)、京東健康(06618.HK)及非藍籌的平安好醫生(01833.HK)跌1.2%至3%不等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.